Onco Wiki / Disease

Polycythemia Vera

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDIS-PV
TypeDisease
Aliases
ErythremiaPVPolycythemia rubra veraСправжня поліцитеміяХвороба Вакеза
Statusreviewed 2026-04-25 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 SRC-RESPONSE-VANNUCCHI-2015

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9950/3
icd_o_3_topography["C42.1"]
icd_10D45
who_classificationPolycythaemia vera (PV) — Ph-negative myeloproliferative neoplasm (per WHO 5th ed.)

Capabilities

Notes

Authored as a separate disease from ET (rather than a single combined PV-ET YAML). Rationale (per myeloid expansion commit message): JAK2 V617F prevalence is essentially universal in PV (~95%) but only ~50% in ET; thrombotic-risk drivers differ (Hct + RBC mass in PV vs platelet count + JAK2 + age in ET); 1L cytoreduction shares HU but PV adds mandatory phlebotomy + low-dose ASA baseline AND ruxolitinib has a PV indication (RESPONSE) distinct from MF. ET YAML reuses overlapping RFs but has its own algorithm. STUB — requires clinical co-lead signoff before publication. Myeloid expansion (heme).

Used By

Actionability

Algorithms

Disease

Indication

Questionnaires

Red flag

Sources